ABL Diagnostics Société anonyme
ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S… Read more
Market Cap & Net Worth: ABL Diagnostics Société anonyme (9BK0)
ABL Diagnostics Société anonyme (F:9BK0) has a market capitalization of $49.18 Million (€47.91 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #38056 globally and #5051 in its home market, demonstrating a -6.29% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ABL Diagnostics Société anonyme's stock price €2.98 by its total outstanding shares 16078405 (16.08 Million).
ABL Diagnostics Société anonyme Market Cap History: 2026 to 2026
ABL Diagnostics Société anonyme's market capitalization history from 2026 to 2026. Data shows growth from $49.18 Million to $49.18 Million (0.00% CAGR).
ABL Diagnostics Société anonyme Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ABL Diagnostics Société anonyme's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 9BK0 by Market Capitalization
Companies near ABL Diagnostics Société anonyme in the global market cap rankings as of March 19, 2026.
Key companies related to ABL Diagnostics Société anonyme by market ranking:
- Veeva Systems Inc Class A (NYSE:VEEV): Ranked #724 globally with a market cap of $28.17 Billion USD.
- BrightSpring Health Services, Inc. Tangible Equity Unit (NASDAQ:BTSGU): Ranked #989 globally with a market cap of $19.86 Billion USD.
- BrightSpring Health Services, Inc. Common Stock (NASDAQ:BTSG): Ranked #2240 globally with a market cap of $6.77 Billion USD.
- HealthEquity Inc (NASDAQ:HQY): Ranked #2273 globally with a market cap of $6.65 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #724 | Veeva Systems Inc Class A | NYSE:VEEV | $28.17 Billion | $186.70 |
| #989 | BrightSpring Health Services, Inc. Tangible Equity Unit | NASDAQ:BTSGU | $19.86 Billion | $139.72 |
| #2240 | BrightSpring Health Services, Inc. Common Stock | NASDAQ:BTSG | $6.77 Billion | $42.10 |
| #2273 | HealthEquity Inc | NASDAQ:HQY | $6.65 Billion | $79.40 |
ABL Diagnostics Société anonyme Historical Marketcap From 2026 to 2026
Between 2026 and today, ABL Diagnostics Société anonyme's market cap moved from $49.18 Million to $ 49.18 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €49.18 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of ABL Diagnostics Société anonyme was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $49.18 Million USD |
| MoneyControl | $49.18 Million USD |
| MarketWatch | $49.18 Million USD |
| marketcap.company | $49.18 Million USD |
| Reuters | $49.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.